Gadobenic acid


Gadobenic acid
Accession Number
DB00743  (APRD00989)
Small Molecule
Approved, Investigational

Gadobenic acid (in the form of gadobenate dimeglumine) is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.

  • Acide gadobenique
  • Acido gadobenico
  • Acidum gadobenicum
  • Gadobenate
  • Gadobenic acid
  • Gadobensäure
External IDs
B 19036 / B 19036/7
Product Ingredients
IngredientUNIICASInChI Key
Gadobenate dimeglumine3Q6PPC19PO127000-20-8OCDAWJYGVOLXGZ-VPVMAENOSA-K
Active Moieties
Gadolinium cation (3+)ionicAZV954TZ9N22541-19-1RJOJUSXNYCILHH-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MultiHanceInjection, solution529 mg/1mLIntravenousBracco Diagnostics Inc2004-11-23Not applicableUs
MultiHanceSolution529 mgIntravenousBracco Imaging S.P.A.2004-10-28Not applicableCanada
MultiHanceInjection, solution529 mg/1mLIntravenousBracco Diagnostics Inc2004-11-23Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Multihance Multipack (Bracco)
CAS number
Average: 667.73
Monoisotopic: 668.09649
Chemical Formula
InChI Key
gadolinium(3+) ion 4-carboxy-8,11-bis(carboxylatomethyl)-5-(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oate



Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.

Associated Conditions

Gadobenate dimeglumine shares the pharmacokinetic properties of the ECF contrast agent gadopentetate dimeglumine; however, gadobenate differs in that is also selectively taken-up by hepatocytes and excreted via the bile (up to 5% of dose). The elimination half-life of gadobenate dimeglumine is approximately 1 hour. It is not metabolized.

Mechanism of action

Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Gadobenate Dimeglumine shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Gadobenate Dimeglumine primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadobenate Dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Not Available
Volume of distribution
Not Available
Protein binding

Plasma protein binding is low, weak, and transient.


Not metabolized.

Route of elimination

Gadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine.

Half life

1 hour

  • 0.093 +/- 0.010 L/hr/kg [healthy male subjects receiving 3 single-dose IV administration with doses from 0.005-0.4 mmol/kg]

Gadolinium-based radiocontrast agents like gadobenate dimeglumine are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirGadobenic acid may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbexinostatThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Abexinostat.
AcarboseAcarbose may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
AcebutololThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Acebutolol.
AceclofenacAceclofenac may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
AceprometazineThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Aceprometazine.
AcetaminophenAcetaminophen may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Gadobenic acid which could result in a lower serum level and potentially a reduction in efficacy.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Gadobenic acid.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available


Synthesis Reference

Pier Lucio Anelli, Pierfrancesco Morisini, Silvia Ceragioli, Fulvio Uggeri, Luciano Lattuada, Roberta Fretta, Aurelia Ferrigato, "Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form." U.S. Patent US20120232151, issued September 13, 2012.

General References
  1. de Haen C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L: Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S161-8. [PubMed:10608412]
  2. Morana G, Salviato E, Guarise A: Contrast agents for hepatic MRI. Cancer Imaging. 2007 Oct 1;7 Spec No A:S24-7. [PubMed:17921081]
  3. Vogl TJ, Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J: Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol. 1992 Apr;158(4):887-92. [PubMed:1546612]
  4. Kirchin MA, Pirovano GP, Spinazzi A: Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998 Nov;33(11):798-809. [PubMed:9818314]
  5. Clement O, Siauve N, Cuenod CA, Vuillemin-Bodaghi V, Leconte I, Frija G: Mechanisms of action of liver contrast agents: impact for clinical use. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. [PubMed:10608397]
  6. Sweetman, Sean C. (2009). Contrast Media. In Martindale : The Complete Drug Reference, 36th Edition 2 Volume Set (36th ed., pp. 1478). Pharmaceutical Press. [ISBN:978-0-85369-840-1]
External Links
PubChem Compound
PubChem Substance
Therapeutic Targets Database
ATC Codes
V08CA08 — Gadobenic acid
AHFS Codes
  • 36:89.00* — Other Diagnostics
FDA label
Download (247 KB)

Clinical Trials

Clinical Trials
0RecruitingDiagnosticMalignant Brain Glioma / Neoplasms, Brain1
1CompletedDiagnosticCentral Nervous System Pathology1
2CompletedDiagnosticAtrial Fibrillation (AF) / Coronary Artery Disease1
2CompletedDiagnosticBlood Brain Barrier Defect / CNS Lesion1
2RecruitingDiagnosticBreast Cancer / Ductal Carcinoma in Situ - Category1
2TerminatedDiagnosticChronic Thromboembolic Pulmonary Hypertension / Pulmonary Arterial Hypertension (PAH)1
3CompletedDiagnosticBreast Cancer1
3CompletedDiagnosticCarotid, Aortic, Renal or Peripheral Artery Disease1
3CompletedDiagnosticPeripheral Vascular Disease Patient1
3CompletedDiagnosticSteno-Occlusive Disease1
3TerminatedDiagnosticCentral Nervous System Diseases1
4CompletedNot AvailableBrain Pathology1
4CompletedDiagnosticBrain Diseases1
4CompletedDiagnosticBrain Lesions1
4CompletedDiagnosticNeoplasms, Brain1
Not AvailableCompletedNot AvailableCentral Nervous System Diseases / Central Nervous System Neoplasms1
Not AvailableCompletedNot AvailableCentral Nervous System Disease / Central Nervous System Neoplasms1
Not AvailableCompletedNot AvailableLiver Lesion / Neoplasms, Hepatic1
Not AvailableCompletedDiagnosticHepatocellular,Carcinoma1
Not AvailableRecruitingNot AvailableCoronary Artery Disease / Coronary Microvascular Disease1
Not AvailableRecruitingNot AvailableDotarem / Gadolinium / Gadolinium Retention / Magnetic Resonance Imaging (MRI) / MultiHance1
Not AvailableRecruitingNot AvailableIntracranial Neoplasm1
Not AvailableTerminatedDiagnosticAdult Anaplastic (Malignant) Meningioma / Adult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Anaplastic Oligodendroglioma / Adult Brain Stem Glioma / Adult Choroid Plexus Neoplasm / Adult Diffuse Astrocytoma / Adult Ependymoblastoma / Adult Ependymoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Grade II Meningioma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Oligodendroglioma / Adult Papillary Meningioma / Adult Pineal Gland Astrocytoma / Adult Pineoblastoma / Adult Primary Melanocytic Lesion of Meninges / Adult Supratentorial Primitive Neuroectodermal Tumor / Disseminated Sclerosis / Malignant Adult Intracranial Hemangiopericytoma / Metastatic Malignant Neoplasm in the Brain / Recurrent Adult Brain Neoplasm1
Not AvailableWithdrawnScreeningCardiac Graft1


  • Bracco diagnostics inc
  • Bracco Diagnostics Inc.
  • Nycomed Inc.
  • Patheon Inc.
Dosage forms
Injection, solutionIntravenous529 mg/1mL
SolutionIntravenous529 mg
Unit descriptionCostUnit
Multihance 529 mg/ml vial6.87USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
Not Available
Predicted Properties
Water Solubility0.768 mg/mLALOGPS
pKa (Strongest Acidic)0.085ChemAxon
pKa (Strongest Basic)9.58ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area213.94 Å2ChemAxon
Rotatable Bond Count20ChemAxon
Refractivity154.36 m3·mol-1ChemAxon
Polarizability48.32 Å3ChemAxon
Number of Rings1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Human Intestinal Absorption-0.9749
Blood Brain Barrier-0.9391
Caco-2 permeable-0.691
P-glycoprotein substrateSubstrate0.8261
P-glycoprotein inhibitor INon-inhibitor0.7702
P-glycoprotein inhibitor IINon-inhibitor0.7288
Renal organic cation transporterNon-inhibitor0.8635
CYP450 2C9 substrateNon-substrate0.8598
CYP450 2D6 substrateNon-substrate0.8006
CYP450 3A4 substrateNon-substrate0.6356
CYP450 1A2 substrateNon-inhibitor0.8637
CYP450 2C9 inhibitorNon-inhibitor0.8597
CYP450 2D6 inhibitorNon-inhibitor0.8675
CYP450 2C19 inhibitorNon-inhibitor0.8851
CYP450 3A4 inhibitorNon-inhibitor0.9349
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9905
Ames testNon AMES toxic0.8062
BiodegradationNot ready biodegradable0.8088
Rat acute toxicity2.3557 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8499
hERG inhibition (predictor II)Non-inhibitor0.6371
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
Not Available


Not classified


Pharmacological action
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
Uniprot ID
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
  1. Port M, Corot C, Violas X, Robert P, Raynal I, Gagneur G: How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol. 2005 Sep;40(9):565-73. [PubMed:16118549]
  2. Wendland MF, Saeed M, Lauerma K, Derugin N, Mintorovitch J, Cavagna FM, Higgins CB: Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI. Magn Reson Med. 1997 Mar;37(3):448-56. [PubMed:9055236]
  3. Cavagna FM, Maggioni F, Castelli PM, Dapra M, Imperatori LG, Lorusso V, Jenkins BG: Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997 Dec;32(12):780-96. [PubMed:9406019]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on April 07, 2020 20:19

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.